UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 


 

SCHEDULE TO

TENDER OFFER STATEMENT

 

UNDER

SECTION 14(D)(1) OR SECTION 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934

 


 

TRIUS THERAPEUTICS, INC.

(Name Of Subject Company (Issuer))

 

BRGO CORPORATION

CUBIST PHARMACEUTICALS, INC.

(Names of Filing Persons (Offerors))

 

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

 

89685K100

(CUSIP Number of Common Stock)

 


 

Thomas J. DesRosier

Senior Vice President, Chief Legal Officer,

General Counsel and Secretary

Cubist Pharmaceuticals, Inc.

65 Hayden Avenue

Lexington, MA 02421

(781) 860-8660

(Name, address and telephone number of person authorized

to receive notices and communications on behalf of filing persons)

 


 

with copies to:

Christopher Comeau

Paul Kinsella

Ropes & Gray LLP

800 Boylston Street

Boston, Massachusetts 02199

Telephone: (617) 951-7000

 

CALCULATION OF FILING FEE

 

Transaction Valuation

 

Amount Of Filing Fee

Not Applicable*

 

Not Applicable*

 


*                  A filing fee is not required in connection with this filing as it relates solely to preliminary communications made before the commencement of a tender offer.

 

o             Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number or the Form or Schedule and the date of its filing.

 

Amount Previously Paid:

 

N/A

 

Form or Registration No.:

 

N/A

 

Filing Party:

 

N/A

 

Date Filed:

 

N/A

 

 

x           Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

 

Check the appropriate boxes below to designate any transactions to which the statement relates:

x                 third-party tender offer subject to Rule 14d-1.

o                   issuer tender offer subject to Rule 13e-4.

o                   going-private transaction subject to Rule 13e-3.

o                   amendment to Schedule 13D under Rule 13d-2.

 

Check the following box if the filing is a final amendment reporting the results of the tender offer:   o

 

 

 



 

ITEM  12.                         EXHIBITS

 

Exhibit
No.

 

Description

99.1

 

Form of communication to infectious disease experts

 

2


Grafico Azioni Trius Therapeutics, Inc. (MM) (NASDAQ:TSRX)
Storico
Da Giu 2024 a Lug 2024 Clicca qui per i Grafici di Trius Therapeutics, Inc. (MM)
Grafico Azioni Trius Therapeutics, Inc. (MM) (NASDAQ:TSRX)
Storico
Da Lug 2023 a Lug 2024 Clicca qui per i Grafici di Trius Therapeutics, Inc. (MM)